Stage 4 Breast Cancer A New  Immunotherapy Treatment Brings Hope to         Stage 4 Cancer PatientsImmunology Strengthens ...
Immunotherapy for cancer and stage 4 cancer provides a complete new way oftargeting metastasis and dealing with the primar...
Natural Killer Cells Vital to Stage 4 Breast Cancer and Stage 4 CancerPatientsDespite the impairments in NK and NKT cell n...
simultaneously depleting it of negative factors that impede its functionality. Depleting thenegative factors is extremely ...
2)     Konjevic G, Spuzic I. Evaluation of different effects of sera of breast cancerpatients on the activity of natural k...
kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004Aug;114(3):379-88.13)    Kubo M, Mori...
Upcoming SlideShare
Loading in …5
×

Stage 4 Breast Cancer A New Immunotherapy Treatment Brings Hope to Stage 4 Cancer Patients

962 views

Published on

http://www.envita.com/conditions-we-treat/cancer/stage-4cancer/stage-4breast-cancer-solutions-that-matter - Stage 4 Breast Cancer Patients have typically exhausted chemotherapy, radiotherapy, and all surgical options.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
962
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Stage 4 Breast Cancer A New Immunotherapy Treatment Brings Hope to Stage 4 Cancer Patients

  1. 1. Stage 4 Breast Cancer A New Immunotherapy Treatment Brings Hope to Stage 4 Cancer PatientsImmunology Strengthens Fight Against Stage 4 cancer and Stage 4Breast CancerThe field of cancer immunology is now more than 30 years old and has developedrapidly, particularly over the last 10 years. Immunotherapy, the use of the stimulatedimmune system to fight off disease, has branched out into different subsets includingimmune system growth factors, monoclonal antibodies, cellular therapies, and evencombinations of two or more of these immunotherapy strategies. Recent advances inadoptive immunotherapy (focused on the expansion of specific disease-fighting whiteblood cells and their infusion into patients) have led to breakthrough discoveries that willprofoundly impact the treatment of stage 4 breast cancer and other stage 4 cancer overthe next decade.A Look at Traditional Breast Cancer and stage 4 cancer ProtocolsBreast cancer treatment in the early stages has, for quite some time, been focused onlumpectomy combined with radio and chemotherapy to increase survival. With latestage or Stage 4 Breast Cancer we typically see more of the same, however, it is notuncommon to see additional forms of radiotherapy and chemotherapy treatments if thepatient had grown refractory (or is not responding to treatment) to the first regimen.
  2. 2. Immunotherapy for cancer and stage 4 cancer provides a complete new way oftargeting metastasis and dealing with the primary site of the cancer all at one time. Dataclearly shows that as tumors and cancer stages progress so do immune blockingmechanisms conjured (up regulated) by cancers to self-protect. By depleting suchnegative immune factors and rebuilding a specialized cancer vaccine that employs thebodys own natural killer cells to fight - Envita has a powerful and innovative method todeal with stage 4 breast cancer and stage 4 cancer using the best immunotherapy.Envita Leads the Field in Stage 4 Breast Cancer ImmunotherapyMultitudes of published studies have demonstrated the effects of adoptive immunetherapy in cancer patients. Envitas renowned medical team assessed the best of thesestudies and focused on the strengths and weaknesses of each. Their findingsestablished a protocol that incorporates only the best procedures for the expansion andapplication of cells as a powerful immunotherapy. Our protocols are based on the mostrecent published research in the field, from some of the most prestigious hospitals anduniversities in the nation and around the world. However, our treatment has beenspecially designed to deal specifically with stage 4 breast cancer and stage 4 cancerpatients immune systems.Cancer Killers for Stage 4 Breast Cancer and Stage 4 CancerIt is common knowledge among scientists and physicians that three types of white bloodcells can be activated by the immune system to kill cancer cells directly: cytotoxic Tlymphocytes (CTLs), natural killer cells (NKs), and natural killer T cells (NKTs). Thesecells are found circulating in the body in low amounts; however, they are a major first-line immune system cancer defense. As cancer progress these cells can decrease innumber and are often times being blocked by the cancer signaling. This plays anessential role in the progression of the disease. Envita has found an effective way toreverse this process.Stage 4 Breast Cancer Patients and Understanding Natural Killer CellsOver the past 20 years, scientific studies have repeatedly shown that breast cancerpatients have significantly lower levels of natural killer cells than healthy individuals. 1-3Additionally, NK and NKT function is observably lower in those with breast cancer,meaning that the immune system is severely impaired.2-5Research also shows that progression of disease in these patients is associated withdecreasing NK activity, and that people with a significant family history of breast cancerhad lower NK cell activity than people with minor family history of breast cancer. 4,6 Thisstrongly suggests that defects in NK activity itself may actually contribute to the onset ofbreast cancer.6 Not surprisingly, breast cancer patients typically have low levels ofinterferon-gamma, a major growth factor for NK cells that is naturally produced by thebody.3
  3. 3. Natural Killer Cells Vital to Stage 4 Breast Cancer and Stage 4 CancerPatientsDespite the impairments in NK and NKT cell number and function seen in cancerpatients, these cells have been successfully expanded from patients via advancedlaboratory techniques - providing the necessary cellular resources for effectiveimmunotherapy.3,5 Published research from Stanford University, the Mayo Clinic, andHarvard University has recently illustrated and supported the importance of natural killercells and natural killer T cells in patients with cancer.In fact, adoptive immunotherapy composed of NK cell infusions has the capacity tocause clinical regressions in patients with non-Hodgkins lymphoma, Hodgkins disease,and leukemia. Moreover, NK cells and cytotoxic T lymphocytes have also been utilizedin breast cancer patients with clinical successes noted. 7,8 In patients with metastaticbreast cancer, NK infusion was well-tolerated and resulted in complete response in 20%of patients.7 In 6 out of 16 patients infused with activated T lymphocytes, objectivetumor regressions were observed. 8 In animal models of breast cancer, the anti-tumoreffects of agents such as interleukin-2 and interleukin-12 were determined to bedependent on NK cells. 9,10 Additionally, the presence of activated NK cells and othertumor-fighting immune cells have proven to be key factors in the response of cancerpatients to drugs such as thalidomide, Gleevec, and paclitaxel. 11-13Envitas Two-fold Stage 4 Breast Cancer and Stage 4 CancerImmunotherapyEnvita Natural Medical Center in its Mexico office is currently utilizing NK cells andCTLs as immunotherapy Treatment for cancer patients. Envitas proprietary immunetherapy vaccine is called AAIT (for autologous adoptive immune therapy,) and there are4 major cell types involved - the great majority being natural killer cells and T cells. Thetypes of cells that make up Envitas treatment are listed below:• Natural killer cells• Natural killer T cells• Cytokine-induced killer cells• Cytotoxic T lymphocytesThe vaccine(s) is compiled by growing a patient’s own antitumor immune cells into thebillions. These cells are then analyzed for activation markers and tested for their abilityto kill cancer cells in the laboratory, then re-infused into the patient.Enhancing the immune system is a major benefit to fighting cancer, but this vaccine-driven routine may be added upon through subtraction. Simply put, we can improveresults by not only bolstering critical components of the immune system, but
  4. 4. simultaneously depleting it of negative factors that impede its functionality. Depleting thenegative factors is extremely important.It is no secret that cancer cells effect the release of T-regulatory cells, or "negative Tcells." The numbers of these cells correlate directly with specific cancer stages -respective to each cancer type. The more advanced the cancer, the higher the T-regulatory cells. These cells block your body’s immune system ability to fight. Theimmune system is the first and last defense against cancer.Naturally, by stepping in and acting to deplete these cells along with other key enzymesthat block critical immune system, cancer cell-killing action will be expeditedexponentially. Imagine your immune system being targeted and ready to go, yetsomething in your body suddenly applies the brakes. This is in fact what most stage 4breast cancer and stage 4 cancer patients are dealing with in regards to high regulatoryT cells. Envitas treatment protocols build a targeted vaccine by using the bodys mostpowerful cancer killers, but also depletes the portion of the immune system that inhibitsthe body from functioning efficiently in such regard.Case in point, there is no treatment (conventional or alternative) that can be effective inthe later stages of cancer if these negative T-cells are not effectively down-regulated.Unlike other immune therapies found in the published literature, Envita’s AAIT can beused as a stand-alone treatment. AAIT can also be given in conjunction with othertherapies that will act to enhance the effects of cells once they are in the patient. This isa key improvement over many of the published studies in the scientific literature.Envita’s AAIT therapy is not just focused on expanding cells in the laboratory; theultimate goal is to also expand them and keep them activated after they are infusedback into the body. Making AAIT next important piece to stage 4 breast cancer andstage 4 cancer therapy.AAIT Available for stage 4 breast cancer at Envita MexicoThe activated natural killer cells in Envitas AAIT are considerably more effective in therealm of tumor obliteration than other similar treatments offered in Mexico or across theglobe. Backed by scientific research and clinical results, Envitas AAIT offers a powerfuloption for Stage 4 Breast Cancer and stage 4 cancer patients who are looking to fightcancer while keeping their immune system intact. If you have any questions concerningEnvita’s AAIT, please consult with our team of physicians and patient educators. Thisparticular therapy is offered in Envita Mexicos international cancer center.References1) Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granularlymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg. 1983Aug;198(2):192-9.
  5. 5. 2) Konjevic G, Spuzic I. Evaluation of different effects of sera of breast cancerpatients on the activity of natural killer cells. J Clin Lab Immunol. 1992;38(2):83-93.3) Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G, Salageanu A.Evidence for immune defects in breast and lung cancer patients. Cancer ImmunolImmunother. 2004 Dec;53(12):1146-52.4) Garner WL, Minton JP, James AG, Hoffmann CC. Human breast cancer andimpaired NK cell function. J Surg Oncol. 1983 Sep;24(1):64-6.5) Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ. Modulation ofhuman Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventionalanticancer therapies. Br J Cancer. 2004 Nov 29;91(11):1880-6.6) Strayer DR, Carter WA, Brodsky I. Familial occurrence of breast cancer isassociated with reduced natural killer cytotoxicity. Breast Cancer Res Treat.1986;7(3):187-92.7) deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J,Rybka W, Whiteside T, Ball E. Posttransplant adoptive immunotherapy with activatednatural killer cells in patients with metastatic breast cancer. J Immunother. 2000Jan;23(1):154-60.8) Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, SteinbergSM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R.Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.J Clin Oncol. 2004 Oct 1;22(19):3886-92.9) Divino CM, Chen SH, Yang W, Thung S, Brower ST, Woo SL. Anti-tumorimmunity induced by interleukin-12 gene therapy in a metastatic model of breast canceris mediated by natural killer cells. Breast Cancer Res Treat. 2000 Mar;60(2):129-34.10) Joshi SS, Tarantolo SR, Kuszynski CA, Kessinger A. Antitumor therapeuticpotential of activated human umbilical cord blood cells against leukemia and breastcancer. Clin Cancer Res. 2000 Nov;6(11):4351-8.11) Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S,Chauhan D, Treon SP, Richardson P, Anderson KC. Molecular mechanisms wherebyimmunomodulatory drugs activate natural killer cells: clinical application. Br JHaematol. 2005 Jan;128(2):192-203.12) Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K,Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I,Crepineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF,Heinrich MC, Mecheri S, Tursz T, Zitvogel L. Novel mode of action of c-kit tyrosine
  6. 6. kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004Aug;114(3):379-88.13) Kubo M, Morisaki T, Matsumoto K, Tasaki A, Yamanaka N, Nakashima H, KurokiH, Nakamura K, Nakamura M, Katano M. Paclitaxel probably enhances cytotoxicity ofnatural killer cells against breast carcinoma cells by increasing perforin production.Cancer Immunol Immunother. 2005 May;54(5):468-76. Epub 2004 Dec 9.

×